Oclacitinib
- CAS No.
- 1208319-26-9
- Chemical Name:
- Oclacitinib
- Synonyms
- JAKi;Apoquel;Oclactinib;PF 03394197;Oclacitinib;PF03394197, >98%;Oclacitinib?, >98%;Dimethyl biphenyl-4;Oclacitinib USP/EP/BP;Oclacitinib PF-03394197
- CBNumber:
- CB52667354
- Molecular Formula:
- C15H23N5O2S
- Molecular Weight:
- 337.44
- MOL File:
- 1208319-26-9.mol
- Modify Date:
- 2023/12/22 19:40:13
| Melting point | 226-228°C |
|---|---|
| Density | 1.316±0.06 g/cm3(Predicted) |
| vapor pressure | 0Pa at 20-25℃ |
| storage temp. | Refrigerator, Under inert atmosphere |
| solubility | DMSO (Slightly), Methanol (Slightly, Sonicated) |
| pka | 11.59±0.40(Predicted) |
| form | Solid |
| color | Off-White to Pale Beige |
| InChI | InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/t11-,12- |
| InChIKey | HJWLJNBZVZDLAQ-HAQNSBGRSA-N |
| SMILES | [C@@H]1(CS(NC)(=O)=O)CC[C@@H](N(C)C2N=CN=C3NC=CC3=2)CC1 |
| LogP | 1.38 at 35℃ and pH7 |
Oclacitinib Chemical Properties,Uses,Production
Description
Oclacitinib is an oral JAK inhibitor that is a drug approved by the U.S. Food and Drug Administration (FDA) for use in canine atopic dermatitis (AD). The U.S. FDA and the European Medical Association have approved a number of JAK inhibitors, including baricitinib, ruxolitinib, federatinib, tofacitinib, upadacitinib, oclacitinib, but some of these drugs are still being studied. Oclacitinib mainly shows activity against JAK1-dependent cytokines and also inhibits the function of JAK2-dependent cytokines. oclacitinib modifies the production of cytokines such as IL-4 and IL-13, which are crucial for B-cell proliferation and maturation in the pathogenesis of pemphigus foliaceus. Oclacitinib could interdict the effects of IL-6, a cytokine involved in the Toll-like receptor 4-originated signaling pathway in the bladder epithelial cells, and IL-8, which could theoretically contribute to a decreased defense against the urinary pathogens[1-4].
Uses
Oclacitinib is a novel Janus kinase (JAK) inhibitor with activity against cytokines involved in allergy.
References
[1] Xin P, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology, 2020; 80: 549-56.
[2] Kalantari Y, et al. A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders. International Immunopharmacology, 2022; 110: 108923.[3] Erickson S, et al. New and emerging treatments for inflammatory itch. Annals of Allergy, Asthma Immunology, 2020; 126: 13-20.
[4] Xu P, et al. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. European Journal of Medicinal Chemistry, 2020; 129: 112155.
Oclacitinib Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Zenfold Sustainable Technologies (ZST) | +91-9945888778 +91-9945888778 | Karnataka, India | 32 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| GIHI CHEMICALS CO.,LIMITED | +8618058761490 | China | 50003 | 58 | Inquiry |
| Henan Bao Enluo International TradeCo.，LTD | +86-17331933971 +86-17331933971 | China | 2503 | 58 | Inquiry |
| Henan Fengda Chemical Co., Ltd | +86-371-86557731 +86-13613820652 | China | 20293 | 58 | Inquiry |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | China | 32836 | 60 | Inquiry |
| career henan chemical co | +86-0371-86658258 +8613203830695 | China | 29888 | 58 | Inquiry |
| SHANDONG ZHI SHANG CHEMICAL CO.LTD | +86 18953170293 | China | 2931 | 58 | Inquiry |